FDA Approved: POTELIGEO — Supplemental Application (Kyowa Kirin, Inc.)

View source ↗

Summary

FDA approved a supplemental application for POTELIGEO (mogamulizumab-kpkc) submitted by Kyowa Kirin, Inc., as part of the drug's regulatory action.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Poteligeo (mogamulizumab)

Snippet

SUPPL AP for POTELIGEO (MOGAMULIZUMAB-KPKC)